XML 102 R39.htm IDEA: XBRL DOCUMENT
v3.25.3

Licensing, Acquisitions and Other Arrangements (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Jun. 30, 2024 | Sep. 30, 2025 | Jun. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Collaborative and license agreements |  |  |  |  |  |
Cash outflows related to acquisitions and investments |  |  |  |  | $ (4,076) | $ (1,232)
Acquired IPR&D and milestones |  | $ 2,680 |  | $ 82 | 3,751 | 1,183
Collaborative arrangement |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Research and development milestone expenses |  | 65 |  | 0 | 185 | 95
Ichnos Glenmark Innovation, Inc. |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Acquired IPR&D and milestones |  | 700 |  |  |  |
Ichnos Glenmark Innovation, Inc. | Collaborative arrangement |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Potential Payments under Agreement Certain Milestones |  | 1,200 |  |  | 1,200 |
Capstan Therapeutics, Inc. |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Acquired IPR&D and milestones |  | 1,900 |  |  |  |
Cash consideration paid to shareholders |  | 2,100 |  |  |  |
Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards |  | 187 |  |  |  |
ADARx Pharmaceuticals, Inc. |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Acquired IPR&D and milestones |  |  | $ 335 |  |  |
ADARx Pharmaceuticals, Inc. | Collaborative arrangement |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Potential Payments under Agreement Certain Milestones |  |  | 7,500 |  |  |
Option fees and exercise payments |  |  | 385 |  |  |
Gubra A/S |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Acquired IPR&D and milestones |  |  | 350 |  |  |
Gubra A/S | Collaborative arrangement |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Potential Payments under Agreement Certain Milestones |  |  | $ 1,900 |  |  |
Celsius Therapeutics |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Cash consideration paid to shareholders | $ 250 |  |  |  |  |
Other Collaboration Arrangements | Collaborative arrangement |  |  |  |  |  |
Collaborative and license agreements |  |  |  |  |  |
Acquired IPR&D and milestones |  | $ 2,615 |  | $ 82 | $ 3,566 | $ 1,088

X
- Definition Cash-Settled, Post-Closing Expense for Employee Incentive and Compensation Awards + References No definition available. + Details
Name: | abbv_CashSettledPostClosingExpenseForEmployeeIncentiveAndCompensationAwards
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Option fees and exercise payments + References No definition available. + Details
Name: | abbv_OptionFeesAndExercisePayments
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period. + References No definition available. + Details
Name: | abbv_PotentialPaymentsUnderAgreementCertainMilestones
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Research and Development Milestone Expenses + References No definition available. + Details
Name: | abbv_ResearchAndDevelopmentMilestoneExpenses
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investments classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_IchnosGlenmarkInnovationInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_CapstanTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_ADARxPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_GubraASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_CelsiusTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_OtherCollaborationArrangementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |